secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-03-28T23:59:59+00:00
Accession:  0000950170-23-010108
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking's VK2735 Phase 1 shows up to 7.8% mean weight loss; Phase 2 obesity trial planned mid-2023
--------------------------------------------------------------------------------

- Placebo-adjusted mean weight loss up to 6.0% (7.8% from baseline) after 28 days of weekly dosing.
- No hypoglycemia reported; 98% of adverse events mild/moderate; one SAE (gallstone obstruction) in a subject with history of cholelithiasis.
- VK2735 half-life ~170-250 hours; plans to evaluate higher doses with longer titration in Phase 2.
- Phase 2 trial in obesity expected to initiate in mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023010108/0000950170-23-010108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023010108/vktx-20230328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer